Overview
Ocrevus Zunovo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, active secondary progressive MS, and primary progressive MS in adults. People must not have an active hepatitis B virus infection and must not have a history of life-threatening reactions to ocrelizumab or hyaluronidase. Before starting treatment, doctors will screen for hepatitis B and evaluate liver function and immune levels. Ocrevus Zunovo is also known by its drug name, ocrelizumab and hyaluronidase-ocsq.

Ocrevus Zunovo is a CD20-directed cytolytic antibody. It works by targeting and eliminating B cells, a type of white blood cell thought to play a role in MS by attacking the protective covering of nerves.

How do I take it?
Prescribing information states that Ocrevus Zunovo is given as a subcutaneous (under the skin) injection in the abdomen by a healthcare professional. It is typically administered every six months, with each injection taking about 10 minutes. People are generally given oral premedication with corticosteroids (such as dexamethasone) and an antihistamine (such as desloratadine) at least 30 minutes before each injection to reduce the risk of reactions. People are generally monitored for at least one hour after the first injection, and for at least 15 minutes after later injections. The drug should be given exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Ocrevus Zunovo include injection reactions, upper respiratory tract infections, skin infections, lower respiratory tract infections, and infusion reactions.

Rare but serious side effects may include life-threatening injection reactions, severe infections (including fatal cases), progressive multifocal leukoencephalopathy (a rare brain infection), reduced levels of immunoglobulins (important immune proteins), increased risk of cancers such as breast cancer, immune-mediated colitis (inflammation of the colon), and serious liver injury.

For more information about this treatment, visit:
Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) Injection, for Subcutaneous Use — Genentech